Related references
Note: Only part of the references are listed.Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
A. J. Tremblay et al.
DIABETES OBESITY & METABOLISM (2011)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia
Robert H. J. Bandsma et al.
ATHEROSCLEROSIS (2010)
Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
Eric A. Schwartz et al.
ATHEROSCLEROSIS (2010)
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight
Geesje M. Dallinga-Thie et al.
ATHEROSCLEROSIS (2010)
Recent insights into factors affecting remnant lipoprotein uptake
Kevin Jon Williams et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Insulin Acutely Inhibits Intestinal Lipoprotein Secretion in Humans in Part by Suppressing Plasma Free Fatty Acids
Mirjana Pavlic et al.
DIABETES (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
Elisa Fabbrini et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice
Y. Moritoh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The correlation between TG vs remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers
Katsuyuki Nakajima et al.
CLINICA CHIMICA ACTA (2009)
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies
Kiwon Ban et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2009)
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Martin Adiels et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans
Helene Duez et al.
CIRCULATION (2008)
Intestinal lipoprotein overproduction in insulin-resistant states
Khosrow Adeli et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M. Bajaj et al.
DIABETOLOGIA (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Overproduction of large VLDL particles is driven by increased liver fat content in man
M Adiels et al.
DIABETOLOGIA (2006)
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
K Al Majali et al.
DIABETOLOGIA (2006)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Determination of apolipoprotein B-48 in serum by a sandwich ELISA
M Kinoshita et al.
CLINICA CHIMICA ACTA (2005)
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
JM Lenhard et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
S Rosenblatt et al.
CORONARY ARTERY DISEASE (2001)
Share Paper
